Alembic Pharma gets USFDA nod to therapeutically equivalent of Symmetrel Tablets
Amantadine Hydrochloride Tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
Vadodara: Drugmaker, Alembic Pharmaceuticals Limited, today announced the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Amantadine Hydrochloride Tablets, 100 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Symmetrel Tablets, 100 mg, of Endo Pharmaceuticals, Inc. (Endo).
Amantadine Hydrochloride Tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.
Amantadine Hydrochloride Tablets, 100 mg have an estimated market size of US$ 13 million for twelve months ending June 2020 according to IQVIA.
Alembic has a cumulative total of 132 ANDA approvals (114 final approvals and 18 tentative approvals) from USFDA.
Read also: Alembic Pharma arm, Curon join hands for cancer drug Tenalisib in Greater China
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company headquartered in Gujarat.
Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.
